Latest News
Updates to our Board of Directors
We have some announcements to make about the HAE Canada Board of Directors. The 2022-2023 Board of Directors was elected at our Annual General Meeting in November. Following
2022 HAEi Global Leadership Workshop
Traditionally, every two years, HAE International (HAEi) hosted the HAE Global Conference where patients, caregivers, member organizations, pharmaceutical companies and physicians joined together to learn and connect. This
CBS Announces Results of the RFP for PPRP
Canadian Blood Services (CBS) Announces the Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP). Through their formulary, CBS provides many patients
The 2022 Virtual Global Walk
To celebrate hae day 🙂 over 5,000 people around the world contributed their steps to the 2022 Virtual Global Walk. Thank you to the 911 Canadians who added their
Health Canada Approves ORLADEYO
We are thrilled to share BioCryst Pharmaceutical's big announcement: Health Canada has approved their oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of HAE attacks in patients 12
Takeda Canada Awarded Tender for TAKHZYRO
Héma-Québec, the organization in Quebec that manages blood and biological products, has awarded a two-year tender for TAKHZYRO® (lanadelumab injection), as the sole option for prophylaxis subcutaneous
HAEi Advocacy Academy
HAE International is offering free, online advocacy courses. This extremely comprehensive program is designed to support people with HAE in everyday life. The courses are delivered in small manageable chunks and can
Our Next Patient Information Update: November 20, 2021
Please join us on Saturday November 20th from 1:00-3:00pm ET for our next Update! Details can also be found on our Upcoming Events page.
Notice of the 2021 AGM
We hope you can join us for our 2021 AGM. Please check your inbox for the invitation and links to register. Please check your spam box if you
Save the Date: Nov 20, 2021
Please mark your calendars! HAE Canada is hosting a Virtual Patient Information Update on November 20th at 1:00pm ET. Speakers, topics and other important details will be shared
Lanadelumab Added to NS Formulary
Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova
Congratulations Heather Dow
Who is Heather Dow? Heather has been supporting HAE Canada in many ways over the years, from providing technical support for our virtual Patient Information Updates and organizing
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
